140 related articles for article (PubMed ID: 34887943)
1. Newly developed dual topoisomerase inhibitor P8-D6 is highly active in ovarian cancer.
Flörkemeier I; Steinhauer TN; Hedemann N; Ölander M; Artursson P; Clement B; Bauerschlag DO
Ther Adv Med Oncol; 2021; 13():17588359211059896. PubMed ID: 34887943
[TBL] [Abstract][Full Text] [Related]
2. High Antitumor Activity of the Dual Topoisomerase Inhibitor P8-D6 in Breast Cancer.
Flörkemeier I; Steinhauer TN; Hedemann N; Weimer JP; Rogmans C; van Mackelenbergh MT; Maass N; Clement B; Bauerschlag DO
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008166
[TBL] [Abstract][Full Text] [Related]
3. The Aza-Analogous Benzo[
Aichinger G; Lichtenberger FB; Steinhauer TN; Flörkemeier I; Del Favero G; Clement B; Marko D
Molecules; 2020 Mar; 25(7):. PubMed ID: 32230817
[TBL] [Abstract][Full Text] [Related]
4. The Novel Dual Topoisomerase Inhibitor P8-D6 Shows Anti-myeloma Activity
Klausz K; Kellner C; Gehlert CL; Krohn S; Wilcken H; Floerkemeier I; Günther A; Bauerschlag DO; Clement B; Gramatzki M; Peipp M
Mol Cancer Ther; 2022 Jan; 21(1):70-78. PubMed ID: 34725192
[TBL] [Abstract][Full Text] [Related]
5. Combined PARP and Dual Topoisomerase Inhibition Potentiates Genome Instability and Cell Death in Ovarian Cancer.
Flörkemeier I; Hillmann JS; Weimer JP; Hildebrandt J; Hedemann N; Rogmans C; Dempfle A; Arnold N; Clement B; Bauerschlag DO
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142413
[TBL] [Abstract][Full Text] [Related]
6. A Dual Topoisomerase Inhibitor of Intense Pro-Apoptotic and Antileukemic Nature for Cancer Treatment.
Meier C; Steinhauer TN; Koczian F; Plitzko B; Jarolim K; Girreser U; Braig S; Marko D; Vollmar AM; Clement B
ChemMedChem; 2017 Mar; 12(5):347-352. PubMed ID: 28099785
[TBL] [Abstract][Full Text] [Related]
7. ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity.
Rumman M; Buck S; Polin L; Dzinic S; Boerner J; Winer IS
Cancer Med; 2021 May; 10(10):3373-3387. PubMed ID: 33932119
[TBL] [Abstract][Full Text] [Related]
8. Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells.
Dasari VR; Carey DJ; Gogoi R
BMC Cancer; 2020 Apr; 20(1):273. PubMed ID: 32245422
[TBL] [Abstract][Full Text] [Related]
9. Tumor- and stromal cell-specific expression of topoisomerase IIα and HER-2/neu in primary and recurrent ovarian cancer: Results of a prospective study.
Chekerov R; Koensgen D; Klaman I; Rosenthal A; Oskay-Oezcelik G; Mustea A; Lightenegger W; Dahl E; Sehouli J
Mol Med Rep; 2009; 2(6):1011-6. PubMed ID: 21475936
[TBL] [Abstract][Full Text] [Related]
10. Progesterone-induced apoptosis in immortalized normal and malignant human ovarian surface epithelial cells involves enhanced expression of FasL.
Syed V; Ho SM
Oncogene; 2003 Oct; 22(44):6883-90. PubMed ID: 14534535
[TBL] [Abstract][Full Text] [Related]
11. Profiling follicle stimulating hormone-induced gene expression changes in normal and malignant human ovarian surface epithelial cells.
Ho SM; Lau KM; Mok SC; Syed V
Oncogene; 2003 Jul; 22(27):4243-56. PubMed ID: 12833147
[TBL] [Abstract][Full Text] [Related]
12. Induction of apoptosis and suppression of clonogenicity of ovarian carcinoma cells with estrogen mustard.
Chen Z; Fadiel A; Jia JF; Sakamoto H; Carbone R; Naftolin F
Cancer; 1999 Jun; 85(12):2616-22. PubMed ID: 10375110
[TBL] [Abstract][Full Text] [Related]
13. BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival.
Marchion DC; Cottrill HM; Xiong Y; Chen N; Bicaku E; Fulp WJ; Bansal N; Chon HS; Stickles XB; Kamath SG; Hakam A; Li L; Su D; Moreno C; Judson PL; Berchuck A; Wenham RM; Apte SM; Gonzalez-Bosquet J; Bloom GC; Eschrich SA; Sebti S; Chen DT; Lancaster JM
Clin Cancer Res; 2011 Oct; 17(19):6356-66. PubMed ID: 21849418
[TBL] [Abstract][Full Text] [Related]
14. Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1/Akt signaling pathway.
Yoshihara M; Kajiyama H; Yokoi A; Sugiyama M; Koya Y; Yamakita Y; Liu W; Nakamura K; Moriyama Y; Yasui H; Suzuki S; Yamamoto Y; Ricciardelli C; Nawa A; Shibata K; Kikkawa F
Int J Cancer; 2020 Apr; 146(8):2268-2280. PubMed ID: 31904865
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-induced apoptosis in epithelial ovarian cancers.
Havrilesky LJ; Elbendary A; Hurteau JA; Whitaker RS; Rodriguez GC; Berchuck A
Obstet Gynecol; 1995 Jun; 85(6):1007-10. PubMed ID: 7770245
[TBL] [Abstract][Full Text] [Related]
16. Microtubule inhibitor, SP-6-27 inhibits angiogenesis and induces apoptosis in ovarian cancer cells.
Kulshrestha A; Katara GK; Ibrahim SA; Patil R; Patil SA; Beaman KD
Oncotarget; 2017 Sep; 8(40):67017-67028. PubMed ID: 28978013
[TBL] [Abstract][Full Text] [Related]
17. Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest.
Al Sawah E; Chen X; Marchion DC; Xiong Y; Ramirez IJ; Abbasi F; Bou Zgheib N; Chon HS; Wenham RM; Apte SM; Judson PL; Lancaster JM
Gynecol Oncol; 2013 Oct; 131(1):207-12. PubMed ID: 23877012
[TBL] [Abstract][Full Text] [Related]
18. Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells.
Syed V; Ulinski G; Mok SC; Ho SM
J Natl Cancer Inst; 2002 Apr; 94(8):617-29. PubMed ID: 11959895
[TBL] [Abstract][Full Text] [Related]
19. Ferroptosis of epithelial ovarian cancer: genetic determinants and therapeutic potential.
Lin CC; Chi JT
Oncotarget; 2020 Sep; 11(39):3562-3570. PubMed ID: 33062192
[TBL] [Abstract][Full Text] [Related]
20. CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion.
Johnson EL; Singh R; Singh S; Johnson-Holiday CM; Grizzle WE; Partridge EE; Lillard JW
World J Surg Oncol; 2010 Jul; 8():62. PubMed ID: 20649989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
